PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Adaptimmune Therapeutics plc (ADAP)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINUS00653A1079
CUSIP00653A107
SectorHealthcare
IndustryBiotechnology

Highlights

Market Cap$258.63M
EPS (TTM)-$0.73
PE Ratio54.96
PEG Ratio0.11
Total Revenue (TTM)$18.36M
Gross Profit (TTM)$7.54M
EBITDA (TTM)-$211.52M
Year Range$0.42 - $2.05
Target Price$2.02
Short %2.02%
Short Ratio3.30

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Adaptimmune Therapeutics plc

Popular comparisons: ADAP vs. SCHD

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Adaptimmune Therapeutics plc, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-100.00%-50.00%0.00%50.00%100.00%150.00%2024FebruaryMarchAprilMayJune
-93.69%
161.12%
ADAP (Adaptimmune Therapeutics plc)
Benchmark (^GSPC)

S&P 500

Returns By Period

Adaptimmune Therapeutics plc had a return of 27.36% year-to-date (YTD) and -0.00% in the last 12 months.


PeriodReturnBenchmark
Year-To-Date27.36%13.87%
1 month-18.55%2.33%
6 months124.44%15.10%
1 year-0.00%22.72%
5 years (annualized)-22.46%13.49%
10 years (annualized)N/A10.85%

Monthly Returns

The table below presents the monthly returns of ADAP, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
202421.06%63.54%0.64%-24.68%-5.04%27.36%
202328.08%-5.35%-38.42%30.28%-28.17%-9.31%1.85%-17.19%-0.03%-30.68%-7.53%58.60%-45.68%
2022-22.13%-10.96%-20.77%-16.50%-16.28%18.06%8.82%7.03%-45.71%32.09%52.82%-32.72%-61.07%
20211.30%1.47%-4.15%6.59%-11.13%-15.31%-16.20%44.82%0.00%-1.93%-18.15%-9.64%-30.43%
2020225.00%-7.18%-24.86%23.53%229.46%-9.58%-6.59%-6.95%-8.28%-43.48%11.09%7.58%349.17%
2019-15.30%-9.86%-2.05%11.63%-27.92%16.18%-18.16%-51.06%-6.21%-41.73%32.97%2.56%-79.13%
201829.19%-11.59%47.18%13.18%4.17%-10.35%-17.61%17.79%17.71%-54.28%-0.65%-6.66%-13.92%
20176.42%-6.50%36.72%-2.18%-2.04%-14.96%16.93%33.33%17.00%-4.15%5.48%-19.32%64.94%
2016-41.38%1.70%13.07%19.19%6.19%-20.80%-0.37%-17.49%5.22%-38.30%-4.14%-2.88%-66.42%
2015-3.56%18.79%-17.89%-27.18%9.22%-10.94%-15.20%33.41%-24.63%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of ADAP is 49, suggesting that the investment has average results relative to other stocks in terms of risk-adjusted performance. This ranking is determined by the cumulative values of the indicators listed below.


The Risk-Adjusted Performance Rank of ADAP is 4949
ADAP (Adaptimmune Therapeutics plc)
The Sharpe Ratio Rank of ADAP is 4646Sharpe Ratio Rank
The Sortino Ratio Rank of ADAP is 5454Sortino Ratio Rank
The Omega Ratio Rank of ADAP is 5151Omega Ratio Rank
The Calmar Ratio Rank of ADAP is 4646Calmar Ratio Rank
The Martin Ratio Rank of ADAP is 4646Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Adaptimmune Therapeutics plc (ADAP) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


ADAP
Sharpe ratio
The chart of Sharpe ratio for ADAP, currently valued at -0.03, compared to the broader market-2.00-1.000.001.002.003.00-0.03
Sortino ratio
The chart of Sortino ratio for ADAP, currently valued at 0.63, compared to the broader market-4.00-2.000.002.004.006.000.63
Omega ratio
The chart of Omega ratio for ADAP, currently valued at 1.07, compared to the broader market0.501.001.502.001.07
Calmar ratio
The chart of Calmar ratio for ADAP, currently valued at -0.03, compared to the broader market0.002.004.006.00-0.03
Martin ratio
The chart of Martin ratio for ADAP, currently valued at -0.09, compared to the broader market-10.000.0010.0020.00-0.09
^GSPC
Sharpe ratio
The chart of Sharpe ratio for ^GSPC, currently valued at 2.14, compared to the broader market-2.00-1.000.001.002.003.002.14
Sortino ratio
The chart of Sortino ratio for ^GSPC, currently valued at 3.04, compared to the broader market-4.00-2.000.002.004.006.003.04
Omega ratio
The chart of Omega ratio for ^GSPC, currently valued at 1.38, compared to the broader market0.501.001.502.001.38
Calmar ratio
The chart of Calmar ratio for ^GSPC, currently valued at 1.71, compared to the broader market0.002.004.006.001.71
Martin ratio
The chart of Martin ratio for ^GSPC, currently valued at 8.02, compared to the broader market-10.000.0010.0020.008.02

Sharpe Ratio

The current Adaptimmune Therapeutics plc Sharpe ratio is -0.03. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of Adaptimmune Therapeutics plc with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.002024FebruaryMarchAprilMayJune
-0.03
2.14
ADAP (Adaptimmune Therapeutics plc)
Benchmark (^GSPC)

Dividends

Dividend History


Adaptimmune Therapeutics plc doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%2024FebruaryMarchAprilMayJune
-95.22%
-0.04%
ADAP (Adaptimmune Therapeutics plc)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Adaptimmune Therapeutics plc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Adaptimmune Therapeutics plc was 97.97%, occurring on Nov 20, 2023. The portfolio has not yet recovered.

The current Adaptimmune Therapeutics plc drawdown is 95.22%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-97.97%Jun 17, 20152123Nov 20, 2023
-14.05%May 8, 201517Jun 2, 20157Jun 11, 201524

Volatility

Volatility Chart

The current Adaptimmune Therapeutics plc volatility is 18.82%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%10.00%20.00%30.00%40.00%2024FebruaryMarchAprilMayJune
18.82%
2.26%
ADAP (Adaptimmune Therapeutics plc)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Adaptimmune Therapeutics plc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items